Fair Prescription Drug Competition Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Fair Prescription Drug Competition Act - Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 501: Fair Prescription Drug Competition Act. 111th Congress. Open America. https://openamerica.io/bill/111-S-501/
"S. 501: Fair Prescription Drug Competition Act." 111th Congress, 2026, Open America, https://openamerica.io/bill/111-S-501/.
S. 501, 111th Cong. (2026), https://openamerica.io/bill/111-S-501/.
[S. 501: Fair Prescription Drug Competition Act](https://openamerica.io/bill/111-S-501/)